CATX Earnings Date: Nov 9, 2026 (Estimated) — Perspective Therapeutics, Inc.
AMEX · Healthcare · Medical Devices
Updated
When is CATX's next earnings date?
Perspective Therapeutics, Inc. (CATX) is expected to report Q3 2026 earnings on Monday, November 9, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.24 on revenue of $56,499.
How did CATX do in its last earnings report?
In its most recent report on Aug 10, 2026 (Q2 2026), Perspective Therapeutics, Inc. posted EPS of -$0.22 versus the -$0.25 estimate, a beat of 18.5%. Revenue was $81,000 against a $90,528 estimate. The stock's 1-day post-earnings move was +6.0%.
How much does CATX stock move after earnings?
CATX beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.0% (up or down) in the day after earnings.
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-10 | Q2 2026 | -0.25 | -0.22 | +18.52% | $81,000 | ✅ Beat | +6.00% | +7.33% | -0.33% |
| 2026-05-11 | Q1 2026 | -0.30 | -0.25 | +16.67% | $76,000 | ✅ Beat | -2.84% | -3.09% | -23.97% |
| 2026-03-16 | Q4 2025 | -0.35 | -0.51 | -45.71% | $43,000 | ❌ Miss | -5.17% | -18.77% | -16.09% |
| 2025-11-10 | Q3 2025 | -0.32 | -0.35 | -9.38% | $209,000 | ❌ Miss | +0.00% | -0.45% | +14.86% |
| 2025-08-13 | Q2 2025 | -0.29 | -0.30 | -3.45% | $290,000 | ❌ Miss | -4.27% | -14.07% | -15.08% |
| 2025-03-26 | Q4 2024 | -0.26 | -0.60 | -130.77% | $234,000 | ❌ Miss | +1.32% | -9.69% | +5.29% |
| 2024-11-12 | Q3 2024 | -0.21 | -0.21 | +0.00% | $369,000 | ➖ Inline | -6.94% | -36.46% | -67.48% |
| 2024-08-12 | Q2 2024 | -0.21 | -0.17 | +19.05% | $526,000 | ✅ Beat | +5.71% | +17.12% | +29.45% |
Showing last 8 quarters.